至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Therapeutic effect of Lipoxin A  in malaria-induced acute lung injury.

J. Leukoc. Biol.. 2018-04; 
PáduaTatiana A,TorresNatalia D,CandéaAndré L P,CostaMaria Fernanda Souza,SilvaJohnatas D,Silva-FilhoJoão Luiz,CostaFabio T M,RoccoPatricia R M,SouzaMariana C,HenriquesMar
Products/Services Used Details Operation
Proteins, Expression, Isolation and Analysis … with LXA 4 (5S,6R,15S‐trihydroxy‐7E,9E,11Z,13E‐eicosatetraenoic acid; Cayman Chemical, Ann Arbor, MI, USA); and infected with P. berghei and treated with both the LXA 4 (ALX) receptor antagonist BOC‐2 (N‐Boc‐Phe‐Leu‐Phe‐Leu‐Phe; GenScript, Piscataway, NJ, USA … Get A Quote

摘要

Acute lung injury (ALI) models are characterized by neutrophil accumulation, tissue damage, alteration of the alveolar capillary membrane, and physiological dysfunction. Lipoxin A  (LXA ) is an anti-inflammatory eicosanoid that was demonstrated to attenuate lipopolysaccharide-induced ALI. Experimental models of severe malaria can be associated with lung injury. However, to date, a putative effect of LXA  on malaria (M)-induced ALI has not been addressed. In this study, we evaluated whether LXA exerts an effect on M-ALI. Male C57BL/6 mice were randomly assigned to the following five groups: noninfected; saline-treated Plasmodium berghei-infected; LXA -pretreated P. berghei-infected (LXA  administ... More

关键词

LXA4 receptor,Plasmodium berghei,cytoskeleton remodeling,lung,specialized proresolving media